PSCH News and Press, PowerShares S&P SmallCap Health Care Portfolio From 07/30/22

Per capita U.S. healthcare spending went from $2,968 in 1980 to $12,531 in 2020 (both in 2020 dollars), more than a threefold increase. Amazon announced its plans to acquire primary healthcare company One Medical for $3.9 billion. I believe this deal represents the catalyst for a sign...

After a difficult first half, healthcare’s defensive capabilities are coming into question, but it outperformed the broader markets on a relative basis. The MSCI World Healthcare Index fell by 10.3% through June 30, 2022, in US dollar terms, compared to a 20.5% decline for the ...

Massive short interest buildup is like tinder for a bullish fire. Good economic news is the match for the short-covering rally. Healthcare stocks look especially good and should outperform. After several tortuous weeks of abnormal volatility and a directionless trading e...

Enhabit appears to be significantly undervalued compared to peers in the same line of business. On an absolute basis, Enhabit looks cheap compared to its future cash flows. As a recent spinoff, Enhabit has come under non-fundamental selling pressure. Thesis Enhabit, ...

As companies adjust to inflation, rising interest rates, and a likely economic slowdown, investors are struggling to compute future earnings and the impact on stock valuations. Broadening the sources of stability can help diversify risk and return potential. Geopolitical risk and ...

RGNX is proceeding towards becoming a pillar of the gene therapy space for ocular diseases. However, it will need time to get there. The company is adequately funded for the journey. REGENXBIO Inc. ( RGNX ) is a developer of genetic treatments for eye diseases. Data ...

Why the economy, practically speaking, may already be in recession. Why defensive sectors may be worth a closer look in the current environment. Market sentiment might be bearish, but that doesn't mean there aren't opportunities. Aggressive moves by central banks...

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...

Coherus, an established biosim developer, partnered with a Chinese company to bring a PD-1 inhibitor to the US. However, the trial was entirely done in China. The BLA was rejected for a different manufacturing reason, however, I remain wary about using Chinese trials after Eli Lil...

How similar will the next three or five years look from the years that immediately preceded the pandemic? And what are the implications for us as global equity investors? We don’t expect anything like the hyperinflation and stagflation we experienced in the 1970s; our outlook s...